The shape of BenevolentAI following the return of co-founder Ken Mulvany has started to crystallise and could see the company return to private hands.

Before setting up BenevolentAI Mulvany was CEO of Proximagen, a UK-listed biotech specialising in neurodegenerative diseases that was sold to Upsher-Smith Laboratories for $553 million in 2012.